Montelukast Für Kinder Im Alter Von 2 Bis 5 Jahren Eurogenerics

Montelukast, the active ingredient in Montelukast Für Kinder Im Alter Von 2 Bis 5 Jahren Eurogenerics, is a leukotriene receptor antagonist presented as an oral tablet for oral use. It is indicated for managing asthma and allergic rhinitis in children aged two to five years.

GNH USA supplies Montelukast Für Kinder Im Alter Von 2 Bis 5 Jahren Eurogenerics as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The product complies with EU regulatory standards and is manufactured under GMP conditions.

Montelukast is a leukotriene receptor antagonist used to treat respiratory and allergic conditions.

- Asthma: improves control and reduces frequency of asthma attacks in children. - Exercise‑induced bronchospasm: prevents bronchoconstriction triggered by physical activity. - Allergic rhinitis: relieves nasal congestion, sneezing and itching associated with seasonal allergies.

Montelukast may cause a range of adverse reactions, varying from mild to serious.

Common Side Effects: - Headache - Abdominal pain - Cough - Nausea

Serious or Rare Side Effects: - Allergic reactions such as rash, angioedema or anaphylaxis - Neuropsychiatric events including agitation, depression or suicidal thoughts - Hepatic enzyme elevation or liver injury - Severe skin reactions such as Stevens‑Johnson syndrome

When prescribing Montelukast for children, several precautions should be observed.

- Age limitation: use is approved for children aged 2‑5 years as indicated. - Contraindication: avoid in patients with known hypersensitivity to montelukast or any formulation components. - Neuropsychiatric monitoring: observe for mood changes, anxiety or behavioral disturbances. - Drug interaction review: assess concomitant medications that may alter montelukast metabolism. - Pregnancy and lactation: safety has not been established; use only if potential benefit justifies the risk. - Store at ambient temperature: keep below 25 °C in the original packaging, protected from moisture.

Montelukast can interact with other medicines, affecting its efficacy or safety.

Major Interactions (Avoid): - Phenobarbital: induces hepatic enzymes, reducing montelukast plasma levels. - Rifampin: strong enzyme inducer that may decrease therapeutic effect. - Carbamazepine: increases metabolism leading to lower exposure. - St. John’s Wort: herbal inducer that can lower montelukast concentrations.

Moderate Interactions (Monitor Closely): - Warfarin: montelukast may alter INR, requiring coagulation monitoring. - Beta‑agonists: combined use may enhance bronchodilator effects. - ACE inhibitors: rare reports of increased bronchospasm when co‑administered. - Oral contraceptives: possible reduction in hormonal efficacy, monitor cycle.